Recently, the 4th CSCO-Hansoh Pharma Oncology Forum was successfully held in Shanghai, bringing together authoritative experts in the field of oncology in China to discuss ways to prevent and treat cancer. At the forum, the clinical trial results of the third-generation EGFR-TKI almonertinib independently developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma" or "Company") attracted the attention of participating experts for its excellent efficacy and safety.

According to 2018 statistics from the National Cancer Center, nearly 800,000 new cases of lung cancer occur each year in China, of which about 85% are non-small cell lung cancer (NSCLC). Lung cancer has a poor prognosis and is one of the malignant tumors with the highest incidence and mortality rates. At present, there are still large unmet clinical needs. Studies have shown that, after treatment with first- or second-generation EGFR inhibitors, about 60% of NSCLC patients have EGFR T790M mutation when the disease progresses. Therefore, the treatment after TKI drug resistance progression has become a highly concerned and urgent problem in clinical treatment.

Almonertinib is a new third-generation EGFR-TKI with independent intellectual property rights, used for the treatment of locally advanced or metastatic NSCLC patients, mainly targeting EGFR T790M drug-resistant mutation. The results of Phase II clinical trials of Almonertinib show that it has good efficacy and safety in the second-line treatment of locally advanced or metastatic NSCLC patients with positive EGFR T790M mutation, being a potential new option for the treatment of such population. At the World Conference on Lung Cancer (WCLC) held in September this year, WCLC officials also spoke highly of the research results of Almonertinib and its comparability with similar international advanced drugs in terms of efficacy.

As a leading anti-tumor drug R&D and production enterprise in China, Hansoh Pharma has committed itself in the field of oncology for many years. The Company launched the first generics of a batch of high-quality anti-tumor drugs such as Zefei (Gemcitabine Hydrochloride for Injection), Pulaile (Pemetrexed Disodium for Injection) and Gainuo (Vinorelbine Tartrate Injection), greatly improving the medication accessibility of patients. After years of R&D and exploration, the Company's first solid tumor innovative drug, Almonertinib, will soon come into the market, which is expected to fill the market gap of the third-generation EGFR-TKI independently developed in China, open a new era of domestic innovative targeted drug therapy, and bring hope for long-term survival to more Chinese patients with advanced NSCLC.

Over the years, Hansoh Pharma has always been in awe of life, putting patients' benefits in the first place and living up to the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China". As a domestic leader in the field of pharmaceutical innovation, the Company will, in the future, continue its dedication to meeting unmet clinical needs, and continuously launch more innovative drugs to improve the health and life quality of human.